HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

Summary

This was a multicenter, randomized, double-blind, placebo-parallel-controlled Phase II clinical study to evaluate the efficacy and safety of HRS9531 Injection compared to placebo in obese subjects with heart failure with preserved ejection fraction. A total of 200 obese subjects with heart failure with preserved ejection fraction would be enrolled. Eligible subjects were randomly assigned to either HRS9531 group or placebo group and were treated with HRS9531 injection or placebo, respectively, for 52 weeks.

Timeline

Start

2024-05-06

Primary completion

2026-01

Completion

2026-01

Drugs

Indications